Sarsia
  • Home
  • About us
    • Profile
    • Funds
    • Track record
  • Team
  • Portfolio
  • News
Velg en side

Vaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study

av Øivind Enger | aug 17, 2020 | News

Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR)  announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO,...

Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer

av Øivind Enger | mai 28, 2020 | News

Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...

Rallybio raises USD 145 mill to develop asset acquired from Prophylix Pharma

av Øivind Enger | mai 20, 2020 | News

US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company’s portfolio of product candidates targeting devastating rare diseases. Rallybio’s lead candidate is RLYB211 that the...

BerGenBio raises Euro 45 million in over subscribed private placement

av Øivind Enger | mai 5, 2020 | News

BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020.  Read...

BerGenBio’s Bemcentinib selected to be fasttracked as potential treatment for COVID-19

av Øivind Enger | apr 30, 2020 | News

BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...
« Tidligere innlegg

Siste innlegg

  • Vaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study august 17, 2020
  • Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer mai 28, 2020
  • Rallybio raises USD 145 mill to develop asset acquired from Prophylix Pharma mai 20, 2020
  • BerGenBio raises Euro 45 million in over subscribed private placement mai 5, 2020
  • BerGenBio’s Bemcentinib selected to be fasttracked as potential treatment for COVID-19 april 30, 2020
  • Vaccibody listed on NOTC januar 27, 2020
  • Vaccibody announces positive clinical trial results november 7, 2019
  • Bergenbio’s Bemcentinib meets primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda® november 7, 2019
  • WindSim and Shanghai Electric Wind Power Group Co. Ltd enter into a strategic cooperation november 4, 2019
  • Rallybio acquires Prophylix´ rare disease programs august 22, 2019
  • SonoClear publishes clinical data mai 23, 2019
  • BerGenBio to present new NSCLC and AML clinical data and biomarker data mai 23, 2019
  • SonoCelar secures NOK 10 mill mai 16, 2019
  • Sarsia Seed Fund II raises NOK 130 mill (€ 14 mill) in second closing. april 23, 2019
  • Vaccibody reports positive results from phase IIa clinical study mars 28, 2019
  • BerGenBio dispute resolved februar 28, 2019
  • Vaccibody to present 4 poster during AACR februar 27, 2019
  • Vaccibody secures NOK 230 million (EUR 23,6 million) februar 14, 2019

Sarsia Seed Management AS
Postboks 7150
5020 Bergen

Visit us at
Ytrebygdsveien 215
Kokstad, Bergen

Privacy and cookie policy

Sarsia Seed Management AS © 2019
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.